JP2023519346A - 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用 - Google Patents

養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用 Download PDF

Info

Publication number
JP2023519346A
JP2023519346A JP2022558289A JP2022558289A JP2023519346A JP 2023519346 A JP2023519346 A JP 2023519346A JP 2022558289 A JP2022558289 A JP 2022558289A JP 2022558289 A JP2022558289 A JP 2022558289A JP 2023519346 A JP2023519346 A JP 2023519346A
Authority
JP
Japan
Prior art keywords
cells
antigen
tumor
modified
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519346A5 (enExample
Inventor
ハンス マンティング，エリック
ローフェルス，イェルン
カウア シン，サトウィンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mendus BV
Original Assignee
Mendus BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mendus BV filed Critical Mendus BV
Publication of JP2023519346A publication Critical patent/JP2023519346A/ja
Publication of JP2023519346A5 publication Critical patent/JP2023519346A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022558289A 2020-03-27 2021-03-26 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用 Pending JP2023519346A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063001189P 2020-03-27 2020-03-27
US63/001,189 2020-03-27
US202063110003P 2020-11-05 2020-11-05
US63/110,003 2020-11-05
PCT/IB2021/052542 WO2021191870A1 (en) 2020-03-27 2021-03-26 Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy

Publications (2)

Publication Number Publication Date
JP2023519346A true JP2023519346A (ja) 2023-05-10
JP2023519346A5 JP2023519346A5 (enExample) 2024-04-04

Family

ID=75562778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558289A Pending JP2023519346A (ja) 2020-03-27 2021-03-26 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用

Country Status (7)

Country Link
US (2) US12091681B2 (enExample)
EP (1) EP4127139A1 (enExample)
JP (1) JP2023519346A (enExample)
CN (1) CN115916963A (enExample)
AU (1) AU2021243864A1 (enExample)
CA (1) CA3172449A1 (enExample)
WO (1) WO2021191870A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
US20240002800A1 (en) * 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
WO2025021860A1 (en) * 2023-07-24 2025-01-30 Vivia Biotech, S.L. Method for producing immune cells for immunotherapy
EP4497821A1 (en) * 2023-07-24 2025-01-29 Vivia Biotech, S.L. Method for producing immune cells for immunotherapy
WO2025229499A1 (en) * 2024-04-29 2025-11-06 Averna Therapeutics Ltd Compositions and methods for modulating t cells
WO2026097098A1 (en) * 2024-11-04 2026-05-07 Board Of Regents, The University Of Texas System Methods and systems for unbiased microfluidic isolation of antigen-specific t cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075385A1 (en) * 2017-10-12 2019-04-18 Board Of Regents, The University Of Texas System T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US136A (en) 1837-03-03 Mode of molding candles
US5994A (en) 1849-01-02 Combined beading-tool and circular shears
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU1583397A (en) 1996-01-30 1997-08-22 Brigham And Women's Hospital Antibodies for modulating cd47-mediated neutrophil transmigration
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US6398748B1 (en) 1999-03-16 2002-06-04 Robert B. Wilson Splint bandage and method
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
WO2001018636A1 (en) 1999-09-09 2001-03-15 American Express Travel Related Services Company, Inc. System and method for authenticating a web page
EP1246646A2 (en) 2000-01-05 2002-10-09 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001066149A2 (en) 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001272932A1 (en) 2000-06-02 2001-12-17 Entremed, Inc Angiostatin and endostatin binding proteins and methods of use
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
EP1346059B1 (en) 2000-11-29 2012-05-23 PCI Biotech AS Photochemical internalization for delivery of molecules into the cytosol
AU2210402A (en) 2000-11-29 2002-06-11 Norwegian Radium Hospital Res Photochemical internalization for virus-mediated molecule delivery into the cyosol
US7282556B2 (en) 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
US20040057935A1 (en) 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
US8247231B2 (en) 2003-07-31 2012-08-21 Wilson Constance N Methods and compositions for producing antigenic responses
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
JP4637749B2 (ja) 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
EP1809669A2 (en) 2004-10-01 2007-07-25 Avidex Ltd T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
JP2006232761A (ja) 2005-02-25 2006-09-07 Osaka Univ 制癌剤
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006137398A1 (ja) 2005-06-21 2006-12-28 The Research Foundation For Microbial Diseases Of Osaka University 癌治療薬
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
CN101370927A (zh) 2005-12-07 2009-02-18 基因特伦尼克斯公司 可变容积电穿孔室以及其方法
CA2669746C (en) 2006-12-14 2017-05-16 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2201100E (pt) 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
JP2011500005A (ja) 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
AU2008285598B2 (en) 2008-05-19 2015-04-16 Dcprime B.V. Method for inducing and accelerating cells
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
EP3156494B8 (en) 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
BRPI0923442A2 (pt) 2008-12-19 2016-01-12 Novartis Ag polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
IL224940A (en) 2010-09-02 2017-06-29 Scripps Research Inst Providing a drug for growth based on nanoparticles
GB201018014D0 (en) 2010-10-26 2010-12-08 Senzagen Ab Analytical methods and arrays for use in the same
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
CN103502439B (zh) * 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2012170250A1 (en) 2011-06-07 2012-12-13 Radiation Control Technologies, Inc. Morpholino oligonucleotides capable of inhibiting cd47-mediated cellular damage and uses thereof
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ME03512B (me) 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
EP2836226B1 (en) 2012-02-24 2017-06-28 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
NL2009102C2 (en) 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2743344A1 (en) 2012-12-11 2014-06-18 DCPrime B.V. Therapeutic cancer vaccines derived from a novel dendritic cell line
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2913871C (en) 2013-05-31 2021-07-13 Cellectis A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
WO2015073801A1 (en) 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
EP3188758B1 (en) 2014-08-08 2023-10-04 The Board of Trustees of the Leland Stanford Junior University Sirp alpha-antibody fusion proteins
ES2751915T5 (es) 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa
WO2016081423A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
HK1245154A1 (zh) 2014-12-30 2018-08-24 细胞基因公司 抗cd47抗体及其用途
AR103868A1 (es) 2015-03-04 2017-06-07 Sorrento Therapeutics Inc Anticuerpos anti-cd47 como agentes terapéuticos
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
WO2016154628A1 (en) 2015-03-26 2016-09-29 Xiuli Wang Bi-specific targeted chimeric antigen receptor t cells
US11213577B2 (en) 2015-04-28 2022-01-04 Albert Einstein College Of Medicine, Inc. Treatment of cancer using recall antigens delivered by attenuated bacteria
CN104804093A (zh) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
CA3172801A1 (en) 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
RU2740672C2 (ru) 2015-08-07 2021-01-19 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
CN116425875A (zh) 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
US11351237B2 (en) 2015-12-22 2022-06-07 Thomas Jefferson University CMV-based intra-tumoral cancer therapies
CA3011097C (en) 2016-01-11 2022-12-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
EP3442541B1 (en) 2016-04-10 2021-11-17 Georgia State University Research Foundation, Inc. Composition for use in treating cancer
WO2017196793A1 (en) 2016-05-09 2017-11-16 Celgene Corporation Cd47 antibodies and methods of use thereof
EP3243522A1 (en) 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
CN118652336A (zh) 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
CN106084052B (zh) 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
JP2019526274A (ja) 2016-07-21 2019-09-19 ヴァック４オール・ピーティーイー・リミテッドＶａｃ４Ａｌｌ Ｐｔｅ． Ｌｔｄ． 抗マラリアワクチンとしてのバイオ融合タンパク質
EP3493827A4 (en) * 2016-08-04 2020-02-26 Memorial Sloan-Kettering Cancer Center COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018075813A1 (en) 2016-10-19 2018-04-26 City Of Hope Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy
US20200140565A1 (en) 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
EP3538557A4 (en) 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODY
TW201819413A (zh) 2016-11-28 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
KR102607101B1 (ko) 2017-01-26 2023-11-29 제트엘아이피 홀딩 리미티드 Cd47 항원 결합 유닛 및 그것의 사용
US10934336B2 (en) 2017-04-13 2021-03-02 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
CN109096395B (zh) 2017-06-20 2022-06-24 华兰生物工程股份有限公司 阻断型cd47纳米抗体及其用途
MX2020001309A (es) 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
WO2019034895A1 (en) 2017-08-18 2019-02-21 Ultrahuman Four Limited LIAISON AGENTS
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
US20210115453A1 (en) 2017-08-31 2021-04-22 Poseida Therapeutics, Inc. Transposon system and methods of use
CN108503708B (zh) 2017-09-01 2021-07-30 北京智仁美博生物科技有限公司 抗人cd47抗体及其用途
CN109422726B (zh) 2017-09-04 2022-10-28 华东理工大学 CD47/SIRPα的阻断剂及其应用
WO2019086573A1 (en) 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
BR112020014202A2 (pt) 2018-01-12 2020-12-01 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol como inibidores de vias de sinalização cd47
CN111629754B (zh) 2018-01-24 2023-10-20 南京传奇生物科技有限公司 不引起显著红血细胞凝集的抗cd47抗体
CN110144009B (zh) 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
BR112020018049A2 (pt) 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso
WO2019179366A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-cd47 antibodies
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN110386984B (zh) 2018-04-17 2022-04-22 杭州尚健生物技术有限公司 结合cd47蛋白的融合蛋白及其应用
CN110577597B (zh) 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
CN112566662A (zh) 2018-06-15 2021-03-26 阿库鲁斯生物科学公司 针对cd47的阻断抗体及其使用方法
WO2020009725A1 (en) 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
CA3105816A1 (en) 2018-07-10 2020-01-16 Precigen, Inc. Ror-1 specific chimeric antigen receptors and uses thereof
CA3104833A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
WO2020019135A1 (zh) 2018-07-23 2020-01-30 中国科学院微生物研究所 一种抗cd47抗体及其应用
WO2020036977A1 (en) 2018-08-13 2020-02-20 Arch Oncology, Inc. Therapeutic cd47 antibodies
KR102587442B1 (ko) 2018-08-31 2023-10-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 항-cd47 항체 또는 그 적용
KR102238563B1 (ko) 2018-09-15 2021-04-09 신귀호 뛰어난 단열성의 통합형 알루미늄 도어, 창문 및 외벽 조립체
US11052144B2 (en) 2019-04-25 2021-07-06 Dcprime B.V. Methods of tumor vaccination

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075385A1 (en) * 2017-10-12 2019-04-18 Board Of Regents, The University Of Texas System T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 67, no. 10, JPN6025014562, 2018, pages 1505 - 1518, ISSN: 0005572201 *
CYTOTHERAPY, vol. Vol.19, No.5, Supp. Supplement 1, JPN6025014563, 2017, pages 10 - 11, ISSN: 0005572202 *

Also Published As

Publication number Publication date
WO2021191870A1 (en) 2021-09-30
US20250084376A1 (en) 2025-03-13
CA3172449A1 (en) 2021-09-30
CN115916963A (zh) 2023-04-04
EP4127139A1 (en) 2023-02-08
US12091681B2 (en) 2024-09-17
AU2021243864A1 (en) 2022-11-03
US20210324332A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
US12570982B2 (en) Altering gene expression in modified T cells and uses thereof
US20250011472A1 (en) Disrupting tumor tissues by targeting fibroblast activation protein (fap)
US20210128617A1 (en) SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
US20250084376A1 (en) Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CA3132375A1 (en) Prostate-specific membrane antigen cars and methods of use thereof
US20240041921A1 (en) Compositions and Methods Comprising Prostate Stem Cell Antigen (PSCA) Chimeric Antigen Receptors (CARs)
US20240002800A1 (en) Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
US20220168407A1 (en) Use of tumor-independent antigens in immunotherapies
US20210322471A1 (en) In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US20250121004A1 (en) Compositions and methods comprising anti-cd38 chimeric antigen receptors (cars)
US20250177442A1 (en) Boosting chimeric antigen receptor cells in the blood
WO2024192156A2 (en) Generation of car modifiers for tumor treatment
HK40112241A (en) Altering gene expression in car-t cells and uses thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251014